Odevixibat

(Bylavy®)

Odevixibat

Drug updated on 11/14/2023

Dosage FormPellet (oral; 200 mcg, 600 mcg); Capsule (oral; 400 mcg, 1200 mcg)
Drug ClassIleal bile acid transporter inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).

Product Monograph / Prescribing Information

Document TitleYearSource
Bylavy (odevixibat) Prescribing Information.2021Albireo Pharma Inc., Boston, MA

Systematic Reviews / Meta-Analyses